NCT06740045View on ClinicalTrials.gov

"Opening the Black Box on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma"

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions

AsthmaChronic Rhinosinusitis With Nasal Polyps

Interventions

BIOLOGICAL

Tezepelumab

10 patients will receive teszpire

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Dr. Andrew Thamboo, MD

OTHER